Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease

Reinisch, WalterDivision of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria (author)

Funding Agency:Sandoz, a Novartis division
The introduction of tumor necrosis factor (TNF) inhibitors has significantly changed the treatment landscape in Crohn's disease (CD). The overall therapeutic achievements with TNF inhibitors such as infliximab, adalimumab, and certolizumab pegol paved the way to push the boundaries of treatment goals beyond symptomatic relief and toward cessation of objective signs of inflammation, including endoscopic remission. Even though these agents are widely used for the treatment of moderate to severe CD, heterogeneity still exists in translating evidence-based guidelines on the use of anti-TNF agents into actual treatment algorithms in CD. This might be due to several reasons including disparities in health expenditure policies; lack of harmonization between countries; and variations in assessment of disease severity, use of disease monitoring tools, or application of treatment targets by physicians. With the advent of biosimilars, patent-free versions of reference biologics are now available to minimize health inequalities in drug availability. In this context, this article aims to provide practical clinical guidance for the use of infliximab and adalimumab biosimilars in patients with moderate to severe CD by outlining different clinical scenarios that patients may encounter during their treatment journey.

Gecse, KrisztinaDepartment of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam University Medical Center, Amsterdam, the Netherlands (author)
Halfvarson, Jonas,1970-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Gastroenterology(Swepub:oru)jshn (author)
Irving, Peter M.Department of Gastroenterology, Guy's and St. Thomas' NHS Foundation Trust, London, UK (author)
Jahnsen, JørgenInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway (author)
Peyrin-Biroulet, LaurentDepartment of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France (author)
Rogler, GerhardDepartment of Gastroenterology and Hepatology, University Hospital, University of Zurich, Zurich, Switzerland (author)
Schreiber, StefanInstitute of Clinical Molecular Biology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany; Clinic of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany (author)
Danese, SilvioIBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy (author)
Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, AustriaDepartment of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam University Medical Center, Amsterdam, the Netherlands (creator_code:org_t)

In:Inflammatory Bowel Diseases: Lippincott-Raven Publishers27:1, s. 106-1221078-09981536-4844

By the author/editor: Reinisch, Walter; Gecse, Krisztina; Halfvarson, Jona ...; Irving, Peter M.; Jahnsen, Jørgen; Peyrin-Biroulet, ...; show more...; Rogler, Gerhard; Schreiber, Stefa ...; Danese, Silvio; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Gastroenterology ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.